Although widespread use of immune checkpoint inhibitors in patients with advanced lung cancer has led to meaningful improvements in survival in younger patients, older patients have not experienced similar survival benefits, new research from Yale Cancer Center shows.
A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.
